^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colorectal Cancer

    Related cancers:
    17h
    Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    18h
    A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis (clinicaltrials.gov)
    P=N/A, N=180, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Sep 2029 --> Dec 2025 | Trial primary completion date: Sep 2027 --> Sep 2025 | Enrolling by invitation --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    18h
    Use of a Colorectal Cancer Screening Decision Support Tool in Primary Care (clinicaltrials.gov)
    P=N/A, N=9205, Completed, Massachusetts General Hospital | Recruiting --> Completed | N=80000 --> 9205 | Trial completion date: Aug 2026 --> Jan 2026 | Trial primary completion date: Apr 2026 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    20h
    A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2026 --> Dec 2027
    Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    20h
    Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=430, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting
    Enrollment open • HEOR
    22h
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    23h
    Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk (clinicaltrials.gov)
    P=N/A, N=15, Completed, University of Illinois at Chicago | N=44 --> 15 | Enrolling by invitation --> Completed
    Trial completion • Enrollment change
    |
    CRP (C-reactive protein)
    23h
    MONAMI: Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Assistance Publique - Hôpitaux de Paris | N=43 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Tumor mutational burden • dMMR • First-in-human
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    volrustomig (MEDI5752) • monalizumab (IPH2201)
    1d
    Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (clinicaltrials.gov)
    P2, N=15, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Circulating tumor DNA
    |
    Signatera™
    |
    AMB-05X
    1d
    Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K) (clinicaltrials.gov)
    P2, N=88, Not yet recruiting, Korea University Anam Hospital
    New P2 trial
    |
    Vectibix (panitumumab) • Fruzaqla (fruquintinib)
    1d
    LiMeT: Advanced Therapies for Liver Metastases (clinicaltrials.gov)
    P=N/A, N=625, Recruiting, IRCCS San Raffaele | N=475 --> 625 | Trial completion date: Jun 2026 --> Jun 2030 | Trial primary completion date: Jun 2026 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • Tumor mutational burden
    1d
    GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients (clinicaltrials.gov)
    P=N/A, N=110, Recruiting, Fondazione del Piemonte per l'Oncologia
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL22 (C-C Motif Chemokine Ligand 22) • IL13 (Interleukin 13) • IL15 (Interleukin 15) • IL4 (Interleukin 4) • IL5 (Interleukin 5)